Parsalmide
Title: Parsalmide
CAS Registry Number: 30653-83-9
CAS Name: 5-Amino-N-butyl-2-(2-propynyloxy)benzamide
Additional Names: 5-amino-O-propynyl-N-butylsalicylamide; 2-propargyloxy-5-amino-N-butylbenzamide
Manufacturers' Codes: MY-41-6
Trademarks: Sinovial (Irbi); Parsal (Midy)
Molecular Formula: C14H18N2O2
Molecular Weight: 246.30
Percent Composition: C 68.27%, H 7.37%, N 11.37%, O 12.99%
Literature References: Prepn: B. Gradnik et al., DE 2029991; eidem, US 3739030 (1970, 1973 both to Soc. Etude Recher. Sci. Med.). Synthesis and pharmacology: A. Pedrazzoli et al., Boll. Chim. Farm. 115, 125 (1976). Effect on gastric secretion in laboratory animals: G. Bertaccini et al., Farmaco Ed. Prat. 34, 482 (1979). Inhibition of platelet aggregation: R. Fantasia et al., Arzneim.-Forsch. 32, 1312 (1982). Clinical comparison with phenylbutazone, q.v., in management of joint pain: A. Bajardi, S. Fantato, Minerva Med. 67, 3371 (1976); S. Menci et al., ibid. 3403. Series of articles on anti-inflammatory activity, pharmacology and toxicology: Boll. Chim. Farm. 115, 135-230 (1976), C.A. 85, 13981-13986 (1976).
Properties: Crystals from ethanol, mp 83-85°. pKa (aq soln, 20°) 4.6 ±0.03. uv max (abs alcohol): 220 ±1, 327 ±2 nm; (water, pH 2): 284 nm (log e 3.39); (water, pH 8.5): 313 nm (log e 3.40). Very soluble in alcohol, chloroform, acetone, ethyl acetate, dioxane; slightly sol in water. Practically insol in petr ether, cyclohexane.
Melting point: mp 83-85°
pKa: pKa (aq soln, 20°) 4.6 ±0.03
Absorption maximum: uv max (abs alcohol): 220 ±1, 327 ±2 nm; (water, pH 2): 284 nm (log e 3.39); (water, pH 8.5): 313 nm (log e 3.40)
Therap-Cat: Anti-inflammatory; analgesic.
Keywords: Analgesic (Non-Narcotic); Anti-inflammatory (Nonsteroidal); Salicylic Acid Derivatives.

Others monographs:
RilmazafoneIsoflupredone2-DeoxystreptamineRitanserin
Granulocyte Colony-Stimulating FactorStrontium IodideFluocortin ButylCardamom
Zinc AcetatePumactantAcetomeroctolSodium Dichromate(VI)
Sodium FormaldehydesulfoxylateAcetaldehyde Sodium BisulfiteLuminolTeriparatide Acetate
©2016 DrugLead US FDA&EMEA